Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 22, 2023
Details : DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 13, 2023
Details : DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 29, 2023
Details : DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 17, 2022
Details : Substantial percentage of patients who received DCVax-L (Dendritic Cell Immunotherapy) in the prior Phase I/II clinical trials have continued in a “long tail” of survival far beyond even the 3 year median survival.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 06, 2022
NW Bio Announces Completion of Further Data Gathering For Phase III Trial
Details : Remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 19, 2020
Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases
Details : Data collection from all of the clinical trial sites for the Company's Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the "Trial") has been completed and all of the sites have signed off on the locking of their data.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 24, 2020
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
Details : The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM).
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 10, 2020
NW Bio to Discuss Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
Details : Northwest Biotherapeutics implements a 331-patient Phase 3 trial of DCVax ® -L for Glioblastoma brain cancer, the findings of which will be presented at the 2019 Annual Meeting of Business.
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 18, 2020
Details : The Company reported that the final data collection process for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer has been progressing steadily despite ongoing difficulties due to coronavirus-related limitations on operations and restrictions ...
Product Name : DCVax-L
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2020
Reset All
